PID1 and central nervous system cancer: Bortezomib mitigated the cisplatin-induced decrease of PID1 protein in a dose-dependent manner in both glioma (LN229, U87) and medulloblastoma (UW228) cells (Fig. 5E–G, Supplementary Fig. S6A).